TPD52, upregulated nearly 2-fold in tumors of poor prognosis patients, has been shown to be overexpressed in colorectal cancer [25] and ovarian cancer [26], and genomic amplification of TPD52 has been seen in prostate cancer [27] and breast cancer [28]. This evidence concerns the gene TPD52 and prostate cancer.